Open SBIR/STTR Funding Opportunities
Open Funding Opportunities
Omnibus Solicitation
NIAAA offers funding through the PHS 2024-2 Omnibus Solicitation program announcement, as well as targeted Notices of Funding Opportunities (NOFOs) and several resources for additional technical assistance, commercialization R&D support, and training programs. Standard due dates are April 5, September 5, and January 5 or the next business day.
- SBIR (PA-24-246) (R43/R44 Clinical Trial Required)
- STTR (PA-24-248) (R41/R42 Clinical Trial Required)
- SBIR (PA-24-245) (R43/R44 Clinical Trial Not Allowed)
- STTR (PA-24-247) (R41/R42 Clinical Trial Not Allowed)
- Standard due dates apply
Omnibus Solicitation Funding Information
Targeted Funding Opportunities
Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System
- SBIR (PAR-24-294; U44 Clinical Trial Optional)
- Next due date: July 15, 2025
Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System
- SBIR (PAR-24-063; U44 Clinical Trial Optional)
- Next due date: July 15, 2025
HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management
- SBIR (RFA-NS-23-006; R43/R44 Clinical Trial Not Allowed)
- STTR (RFA-NS-23-007; R41/R42 Clinical Trial Not Allowed)
- Next due date: April 4, 2025
Please note: The SBIR and STTR Extension Act of 2022 (the Act) includes major changes to the SBIR/STTR program, including:
- Increased minimum performance standards (refer to NOT-OD-23-092),
- Pre- and post-award foreign disclosure requirements (refer to NOT-OD-23-139)
- Changes to the peer review criteria.
Scientific Contact:
Megan Ryan, M.B.A.
Phone: 301-443-4225
Email: [email protected]
Grants Management Contact:
Jeff Thurston
Phone: 301-443-9801
Email: [email protected]
Commercialization Resources
NIH Commercialization Readiness Pilot (CRP) Program
Funding and technical assistance to help develop regulatory strategy and prepare for submission for U.S. Food and Drug Administration and other agencies, as well as other support for key studies, compliance activities, and other research to advance to commercialization.
- SBIR/STTR (PAR-23-219)
Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late-Stage Development - Clinical Trial Not Allowed - SBIR/STTR (PAR-23-220)
Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late-Stage Development - SB1 Clinical Trial Required - See NOT-OD-25-014 for budget updates
Innovation Corps (I-CorpsTM) at NIH Program for NIH and CDC Translational Research
An intensive 8-week entrepreneurial training course for active Phase I SBIR and STTR awardees.
- Phase I SBIR and STTR Admin Supplement - Clinical Trial Not Allowed
- Learn more
- Apply through NIH ASSIST
Technical and Business Assistance
The NIH Technical and Business Assistance (TABA) administrative supplement helps small businesses make better technical decisions, solve technical problems, minimize technical risks, and develop and commercialize new products and processes. For more information, view NOT–OD–24–077.
All applicants can request additional funding for technical and business services, such as access to technologies or support on product sales, intellectual property protections, market research, and planning. Requests should be made within the application under “F. Other Direct Costs, lines 8-10” and labeled “Technical and Business Assistance” on the budget. Grantees may also apply for TABA funding through the Administrative Supplement Parent, PA-20-272, if they did not do so through their application.
- Phase I has a cap of $6,500 per year
- Phase II has a cap of $50,000 for the life of the project
For grantees who have not applied for TABA in their initial Phase I submission, the TABA Needs Assessment Report provides a third party, unbiased assessment of your progress in 4 technical and business areas that are critical to success in the competitive healthcare marketplace:
- Intellectual Property/Barriers to Entry
- Market Needs/Competitive Advantages
- Regulatory, Manufacturing, and/or Clinical Plan
- Business Model Profitability
The report will also suggest the highest priority steps you can take to improve the commercial potential of your product or service. There is no cost for this report and the time commitment for participation is minimal. Needs Assessment Reports will be completed in 2-3 months.
Eligibility: Applicants must have had an active NIH SBIR or STTR Phase I or Phase I Fast-Track award (grant or contract) within the past two years. For companies with multiple awards, only one project will be considered for the program. Small businesses that have received TABA funding within their Phase I award are not eligible to participate.
Deadline: The Needs Assessment Program will be open throughout the year. Requests will be reviewed on a monthly basis with notification of status within 60 days of submission.
To learn more about TABA, visit the NIH SBIR STTR webpage or read FAQs here.